A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Phase of Trial: Phase II
Latest Information Update: 29 Dec 2017
At a glance
- Drugs Capmatinib (Primary) ; Ceritinib (Primary) ; Entrectinib (Primary) ; Regorafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 20 Dec 2017 Planned End Date changed from 1 Sep 2018 to 30 Sep 2020.
- 20 Dec 2017 Planned primary completion date changed from 1 Sep 2017 to 30 Sep 2018.
- 20 Dec 2017 Status changed from active, no longer recruiting to recruiting.